Altria Stock Trades at a Discount: Should You Buy, Sell or Hold?

Altria trades at a 12.1x forward P/E discount versus the tobacco industry’s 15.47x average and has risen 9.6% over the past month, supported by Q2 2026 adjusted EPS growth of 2.8% to $1.48. However, domestic cigarette shipment volume fell 3.2% year over year (4.5% inventory-adjusted), while oral tobacco revenue declined 5.3% and adjusted OCI dropped 8%. Consensus 2026 and 2027 EPS estimates each declined by $0.03 over 60 days to $5.67 and $5.84, supporting the article’s Hold view despite on! PLUS expansion to 120,000 stores.

Analysis

MO’s valuation discount is not, by itself, a catalyst: the market is assigning a lower multiple to a domestic franchise whose profit defense increasingly depends on taking price while absorbing more promotional spend and unfavorable mix. That model can sustain cash distributions for several quarters, but it becomes nonlinear once downtrading accelerates—discount-brand gains protect volume but dilute the very pricing/mix equation supporting EPS. The near-term read-through is more negative for MO than for PM, whose geographic diversification and smoke-free scale give it a cleaner volume-to-growth bridge.

The key competitive datapoint is not broad oral-category growth, but whether on! PLUS can regain pouch share after distribution normalizes. A successful higher-strength/flavor rollout could lower customer-acquisition costs and justify a modest multiple rerating over the next 6-12 months; failure would leave MO funding promotions in a structurally inferior position against ZYN and likely force further estimate cuts. BTI is the relevant value alternative: it has comparable regulatory exposure but a lower valuation starting point, so MO’s relative outperformance is vulnerable if investors rotate from momentum into deeper tobacco value.

Consensus may be too focused on reported EPS resilience and too little on the quality of that resilience. Cigarette demand deterioration, discount mix, and promotional intensity can coexist with near-term EPS delivery, but they reduce future pricing headroom and make the dividend/FCF narrative more rate-sensitive. There is no high-conviction directional trade until scanner data establishes whether retail-share losses are reversing; the next earnings call and management’s full-year pricing-versus-volume commentary are the 1-3 month catalysts.

Key Decisions for Investors

• Maintain a neutral-to-underweight MO stance after the recent momentum move; do not chase the multiple discount. Reassess only if nicotine-pouch share improves for two consecutive monthly scanner-data reads and management holds full-year EPS guidance without incremental promotion spending.
• Implement a 3-6 month relative-value pair: long BTI / short MO in equal dollar size. The trade expresses MO-specific execution and estimate-revision risk while retaining tobacco-sector defensiveness; cover if MO’s pouch share inflects positively or if BTI faces a material U.S. regulatory setback.
• For long-only tobacco exposure, favor PM over MO for the next 6-18 months despite its premium valuation, provided smoke-free revenue growth remains intact. The falsifier is decelerating smoke-free growth combined with renewed combustible-volume weakness, which would remove the justification for PM’s premium.
• Set an earnings alert on MO: a further reduction in forward EPS expectations, oral-segment margin deterioration, or inventory-adjusted cigarette declines worsening beyond the current run rate would support adding to the MO short leg; evidence that promotions are declining while share improves would invalidate it.